Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Acute Lymphoblastic Leukemia
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly used in the treatment of ALL. This formulation of the drug can be given intrathecally (into the spinal fluid), and is released slowly over a longer period, about two weeks. This allows a longer exposure of t...
Liposomal cytarabine (DepoCyte) is a new formulation of the drug cytarabine, a drug commonly used in the treatment of ALL. This formulation of the drug can be given intrathecally (into the spinal fluid), and is released slowly over a longer period, about two weeks. This allows a longer exposure of the drug to the central nervous system, and requires fewer intrathecal injections for the patient.
Tracking Information
- NCT #
- NCT01593488
- Collaborators
- Santobono-Pausilpon Hospital
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- University of Bologna
- Investigators
- Principal Investigator: Rosanna Parasole, M.D. Santobono - Pausilipon Hospital Principal Investigator: Massimo Di Maio, M.D. National Cancer Institute, Naples Principal Investigator: Francesco Perrone, M.D., Ph.D. National Cancer Institute, Naples Principal Investigator: A. Pession Policlinico S. Orsola-Malpighi, Bologna Principal Investigator: William Morello Policlinico S. Orsola-Malpighi, Bologna Principal Investigator: E. Strocchi University of Bologna
Get Well Soon